Arizona Tribune - Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB^® and has commenced trading on OTCQB under the symbol "PTIX."

The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification and bid price standards. The upgrade strengthens Protagenic's public market profile and is expected to improve investor visibility, support trading liquidity and provide access to real-time market quotes through OTC Markets.

Protagenic continues to advance PT00114, its lead program for treatment-resistant depression and anxiety. The Company recently completed a successful Phase 1 multiple-dose safety study, demonstrating a clean safety and tolerability profile, and remains on track to begin Phase 2 enrollment in 2026.

"Upgrading to OTCQB is a meaningful step for Protagenic," said Bill Nichols, President of Protagenic Therapeutics. "It gives investors better market visibility, real-time quotation access and a more transparent public-market platform as we advance PT00114 toward Phase 2. We are building momentum in the clinic and maintaining the public-company standards shareholders should expect."

About PT00114
PT00114 is a first-in-class investigational compound targeting the teneurin C-terminal associated peptide (TCAP) pathway, a novel mechanism of action being studied for treatment-resistant depression, anxiety and related stress disorders.

About Protagenic Therapeutics
Protagenic Therapeutics, Inc. (OTCQB:PTIX) is a clinical-stage biopharmaceutical company focused on developing novel treatments for stress-related neurological disorders. The Company is headquartered in New York, NY. For more information, please visit www.protagenic.com

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this current report include, without limitation, statements regarding the Company's expected filing of its Quarterly Report on Form 10-Q, the Company's planned appeal before the Panel, and the continued listing of the Company's securities pending the appeal. Forward-looking statements are statements that are not historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, that there can be no assurance that the Company will file the Form 10-Q, that there can be no assurance that the Company will otherwise meet Nasdaq compliance standards, that there can be no assurance that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company can agree to or ultimately meet applicable Nasdaq requirements for any such relief, and the other important factors described under the caption "Risk Factors" in the Company's filings with the SEC. Any forward-looking statement made by the Company in this current report is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Company Contact:

Alexander K. Arrow, MD, CFA
Chief Financial Officer
Protagenic Therapeutics, Inc.
149 Fifth Ave, Suite 500, New York, NY 10010
Tel: 213-260-4342
Email: [email protected]

SOURCE: Protagenic Therapeutics, Inc.

View the original press release on ACCESS Newswire

M.Robinson--AT